Whether adjuvant immune checkpoint inhibition cuts recurrence risk in patients with localized renal cell carcinoma, as the phase III KEYNOTE-564 study showed, is unclear. Three other adjuvant trials—CheckMate-914, IMmotion010, and PROSPER—recently reported no disease-free survival improvement, casting some doubt on the utility of this approach.

You do not currently have access to this content.